Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. (Nasdaq: CBUS) is an agricultural technology company that develops and licenses gene-edited plant traits to seed companies, with a focus on productivity traits for major row crops. The CBUS news page on Stock Titan aggregates company announcements, business updates, regulatory milestones, and collaboration news directly relevant to Cibus’ trait development and commercialization plans.
In its news releases, Cibus highlights progress in rice herbicide-tolerance traits HT1 and HT3, including material transfer agreements and a non-binding letter of intent with organizations and companies in Latin America to introduce these traits into elite rice germplasm and to prepare for commercialization in key rice-producing markets. The company also reports on collaborations aimed at bringing its gene editing technologies to India’s rice seed industry through strategic advisory partnerships.
News coverage for CBUS also includes updates on canola trait programs, such as positive field trial results for its HT2 herbicide-tolerance trait in North America and field trials for pod shatter reduction and disease resistance traits in winter oilseed rape. Additional items describe Cibus’ sustainable ingredients program, where the company has completed pre-commercial pilot runs for certain biofragrance products and received initial payments associated with commercialization efforts.
Investors and observers can use the CBUS news feed to follow Cibus’ participation in regulatory developments around gene editing in regions such as the European Union, the United Kingdom, North America and Ecuador, as well as corporate governance changes, board appointments, workforce adjustments and strategic focus updates. Regular visits to this page provide a consolidated view of how Cibus’ trait pipeline, partnerships and regulatory environment are evolving over time.